PMID- 20215339
OWN - NLM
STAT- MEDLINE
DCOM- 20110602
LR  - 20220317
IS  - 1879-0844 (Electronic)
IS  - 1388-9842 (Linking)
VI  - 12
IP  - 5
DP  - 2010 May
TI  - Mid-regional pro-adrenomedullin as a novel predictor of mortality in patients 
      with chronic heart failure.
PG  - 484-91
LID - 10.1093/eurjhf/hfq031 [doi]
AB  - AIMS: Adrenomedullin (ADM) is a vasodilatory peptide. Its plasma levels or its 
      precursors have not been evaluated in large populations of patients with chronic 
      heart failure (CHF). We sought to explore mid-regional proADM (MR-proADM). 
      METHODS AND RESULTS: We assessed MR-proADM in 501 CHF patients [age 63 +/- 11 
      years, New York Heart Association (NYHA) class I/II/III/IV 9/44/39/8%, median 
      N-terminal pro-B-type natriuretic peptide (NT-proBNP) 878 pg/mL (interquartile 
      range-IQR 348-2480 pg/mL), median left ventricular ejection fraction (LVEF) 31% 
      (IQR 25-37%)]. Mid-regional pro-adrenomedullin levels (median 0.64 nmol/L, IQR 
      0.49-0.87 nmol/L) increased with NYHA class (P < 0.0001). During 1-year 
      follow-up, 70 patients (14%) died. Increasing MR-proADM was a predictor of poor 
      survival at 12 months (hazard ratio 1.82, 95% confidence interval 1.24-2.66, P = 
      0.002) after multivariable adjustment. In receiver-operating characteristic curve 
      analysis of 12-month survival, the area under the curve for MR-proADM and 
      NT-proBNP was similar (P = 0.3). Comparison of Cox proportional hazard models 
      using the likelihood ratio chi(2) statistic showed that both NT-proBNP and 
      MR-proADM added prognostic value to a base model of LVEF, age, creatinine, and 
      NYHA class. Adding MR-proADM to the base model had stronger prognostic power than 
      adding NT-proBNP (both P < 0.01). CONCLUSION: Mid-regional pro-adrenomedullin is 
      an independent predictor of mortality in CHF patients, which adds prognostic 
      information to NT-proBNP.
FAU - von Haehling, Stephan
AU  - von Haehling S
AD  - Applied Cachexia Research, Department of Cardiology, Charite Medical 
      School-Campus Virchow-Klinikum, 13353 Berlin, Germany. 
      stephan.von.haehling@web.de
FAU - Filippatos, Gerasimos S
AU  - Filippatos GS
FAU - Papassotiriou, Jana
AU  - Papassotiriou J
FAU - Cicoira, Mariantonietta
AU  - Cicoira M
FAU - Jankowska, Ewa A
AU  - Jankowska EA
FAU - Doehner, Wolfram
AU  - Doehner W
FAU - Rozentryt, Piotr
AU  - Rozentryt P
FAU - Vassanelli, Corrado
AU  - Vassanelli C
FAU - Struck, Joachim
AU  - Struck J
FAU - Banasiak, Waldemar
AU  - Banasiak W
FAU - Ponikowski, Piotr
AU  - Ponikowski P
FAU - Kremastinos, Dimitrios
AU  - Kremastinos D
FAU - Bergmann, Andreas
AU  - Bergmann A
FAU - Morgenthaler, Nils G
AU  - Morgenthaler NG
FAU - Anker, Stefan D
AU  - Anker SD
LA  - eng
PT  - Journal Article
DEP - 20100309
PL  - England
TA  - Eur J Heart Fail
JT  - European journal of heart failure
JID - 100887595
RN  - 0 (ADM protein, human)
RN  - 0 (Peptide Fragments)
RN  - 0 (pro-brain natriuretic peptide (1-76))
RN  - 114471-18-0 (Natriuretic Peptide, Brain)
RN  - 148498-78-6 (Adrenomedullin)
SB  - IM
MH  - Adrenomedullin/*analysis/blood
MH  - Cardiovascular Diseases/mortality
MH  - Confidence Intervals
MH  - Europe
MH  - Female
MH  - Heart Failure/epidemiology/*mortality/pathology
MH  - Humans
MH  - Immunoassay
MH  - Male
MH  - Middle Aged
MH  - Multivariate Analysis
MH  - Natriuretic Peptide, Brain
MH  - Peptide Fragments
MH  - Prognosis
MH  - Proportional Hazards Models
MH  - Prospective Studies
MH  - ROC Curve
MH  - Statistics as Topic
MH  - Statistics, Nonparametric
MH  - Survival Analysis
MH  - Treatment Outcome
MH  - *Vasodilation
EDAT- 2010/03/11 06:00
MHDA- 2011/06/03 06:00
CRDT- 2010/03/11 06:00
PHST- 2010/03/11 06:00 [entrez]
PHST- 2010/03/11 06:00 [pubmed]
PHST- 2011/06/03 06:00 [medline]
AID - hfq031 [pii]
AID - 10.1093/eurjhf/hfq031 [doi]
PST - ppublish
SO  - Eur J Heart Fail. 2010 May;12(5):484-91. doi: 10.1093/eurjhf/hfq031. Epub 2010 
      Mar 9.